ReviewInternational journal of molecular sciences2022
Molecular Management of High-Grade Serous Ovarian Carcinoma.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 42 citations in OpenAlex.
- Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases.Cancers · 2026Article
- Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.British journal of cancer · 2026Article
- A clinical-radiomics model based on MRI sub-regions of gluteus maximus for recurrence prediction in high-grade serous ovarian cancer.Abdominal radiology (New York) · 2026Article
- From Yin-deficiency to therapy: molecular mechanisms and drug discovery in high-grade serous ovarian cancer.Journal of ovarian research · 2026Article
- Multitask deep learning models for ultrasound image analysis: identification of high-grade serous ovarian cancer and segmentation of tumor regions and intratumoral solid components.Journal of ovarian research · 2026Article
- Unexplained Inguinal Adenopathy Leading to the Diagnosis of Metastatic High-Grade Serous Ovarian Carcinoma.Cureus · 2026Article
- High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.International journal of molecular sciences · 2026Review
- Integrative Multi-Omics Analysis Reveals Molecular Signatures of Recurrence in Paired Primary and Recurrent High-Grade Serous Ovarian Cancer.International journal of molecular sciences · 2026Article
- Article
- Synchronous Ovarian and Cervical Malignancies: A Case Report of Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and Niraparib Maintenance.International journal of women's health · 2026Article
- ALKBH5-Mediated ITGB1 m6A Modification in Ovarian Cancer Progression and Immune Evasion.NPJ precision oncology · 2025Article
- Detection of probable phytochemical inhibitors targeting kallikrein related peptidase 7 (KLK7) in ovarian cancer through molecular dynamics and virtual screening approaches.Scientific reports · 2025Article
- Inflammatory Indices vs. CA 125 for the Diagnosis of Early Ovarian Cancer: Evidence from a Multicenter Prospective Italian Cohort.Journal of personalized medicine · 2025Article
- Aggressive serous ovarian cancer subtype defined by high centrality lncRNA profiles and master transcription factors.Scientific reports · 2025Article
- LINC02888 promotes HGSOC progression and immune evasion via PPIB-mediated stabilization of LAPTM5 mRNA and inhibition of RIG-I-like receptor signaling.Journal of translational medicine · 2025Article
- Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution.Pathologica · 2025Article
- TIMP1 Overexpression in Ovarian Cancer Spheroids: Implications for Prognosis, Resistance, and Metastatic Potential.Cancers · 2025Article
- MORE interpretable multi-omic regulatory networks to characterise phenotypes.Briefings in bioinformatics · 2025Article
- A rare presentation of high-grade serous ovarian carcinoma with ulcerating inguinal lymph node metastasis: a case report.Journal of surgical case reports · 2025Article
- PNO1 enhances ovarian cancer cell growth, invasion, and stemness via activating the AKT/Wnt/β-catenin pathway.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
High-grade serous ovarian carcinoma (HGSOC) represents the most common form of epithelial ovarian carcinoma. The absence of specific symptoms leads to late-stage diagnosis, making HGSOC one of the gynecological cancers with the worst prognosis. The cellular origin of HGSOC and the role of reproductive hormones, genetic traits (such as alterations in P53 and DNA-repair mechanisms), chromosomal instability, or dysregulation of crucial signaling pathways have been considered when evaluating prognosis and response to therapy in HGSOC patients. However, the detection of HGSOC is still based on traditional methods such as carbohydrate antigen 125 (CA125) detection and ultrasound, and the combined use of these methods has yet to support significant reductions in overall mortality rates. The current paradigm for HGSOC management has moved towards early diagnosis via the non-invasive detection of molecular markers through liquid biopsies. This review presents an integrated view of the relevant cellular and molecular aspects involved in the etiopathogenesis of HGSOC and brings together studies that consider new horizons for the possible early detection of this gynecological cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.